After reporting stellar data at ASH, Terns is acquired for $6.7bn.
ApexOnco Front Page
Recent articles
Dareon-Lung-1 will test obrixtamig plus Tecentriq and chemo in small-cell lung cancer.
Talapro-3 could help move Talzenna into earlier prostate cancer.
The Chinese company will start the first of four pivotal trials of its PD-L1 ADC in April.
Single, double and even triple-payload ADCs will be presented at the meeting.
First human data on MK-2010 are imminent.
The company reveals its anti-GPRC5D T-cell engager.
The company’s TRPV1 antagonist looks doomed.
